Article Text

Download PDFPDF
PS-092 Pharmacological treatment of the comorbidities of patients with Multiple Sclerosis
  1. T Sánchez Casanueva1,
  2. JJ Márquez Nieves1,
  3. E Zamora Ferrer2,
  4. E Jerez Fernández2,
  5. M Heredia Benito2,
  6. JM Tenías Burillo3
  1. 1Hospital General de Tomelloso, Pharmacy, Tomelloso, Spain
  2. 2Hospital General La Mancha Centro, Pharmacy, Alcázar de San Juan, Spain
  3. 3Hospital General La Mancha Centro, Research Support Unit, Alcázar de San Juan, Spain


Background Patients with Multiple Sclerosis (MS) can present a wide range of symptomatic problems associated with disease progression.

Purpose To review the treatments MS patients take at home to manage their comorbidities and to check for possible drug interactions.

Materials and methods On 30 September 2013 all patients with MS treated with immunomodulatory drugs were identified with the hospital pharmacy dispensing software Farmatools. The domiciliary drugs prescribed and dispensed in the ambulatory pharmacy were identified with the primary care electronic medical record. Additionally, their indications were identified by means of the primary care and the hospital electronic medical record. A descriptive analysis of drugs and indications was performed. The appropriateness of the comorbidities treatment was assessed by comparing prescriptions with registered indications. The possible interactions between the domiciliary and the immunomodulatory treatments were checked using “Stockley’s Drug Interactions” and the Micromedex database.

Results 68 patients were selected with a mean age of 40.5 ± 8.8 years, 19 men (27.9%) and 49 women (72.1%). 66 with relapsing remitting MS (97.1%) and 2 with secondary progressive MS (2.9%). 32 patients were being treated with interferon beta-1a, 10 with interferon beta-1b, 13 with glatiramer acetate and 13 with fingolimod. 48 domiciliary drugs in 74 prescriptions were identified. Amantadine (7 prescriptions), levothyroxine (5), lorazepam (4), amitriptyline (3), citalopram (3), clonazepam (3), clorazepate dipotassium (3), fluoxetine (2), budesonide (2), omeprazole (2) and alprazolam (2) amounted to approximately half of the prescriptions. The indications of depression, fatigue, spasticity, anxiety, pain and asthma accounted for more than half of cases. All patients received appropriate prescriptions compared to registered indications. There was no interaction between the immunomodulatory and the domiciliary treatments.

Conclusions Patients with advanced MS need several medicines to manage the comorbidities associated with the evolution of the disease. The review of possible drug interactions contributed to safer and more effective drug treatment.

No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.